Research & Development

妹妹干狠狠干草榴社区1024/草榴社区2018最新网站药品高毛利时代将终结 "4+7"政策下零售药店风险几何


  黎曼坐在窗邊的寬大搖椅上微笑听著,偶爾還會指點一下他偷懶跳過去的地方,她幼年的時候也學過幾樣樂器,後來興趣都放在了繪畫上,已經很少踫這些了。   除了這一句話,他不知道該說什麼,他做錯過一次事,這次他想改。妹妹干 狠狠干   陸老大這才瞧見旁邊還站著一個老頭,正在那一臉諂媚地笑著搓手,他皺眉道︰“這老頭干什麼的?”   黎舟只好把那點零錢收起來,端了面上去。草榴社区1024/草榴社区2018最新网站   刁明山笑了道︰“大少爺說的是,我來的時候老爺子也這麼跟我說的,剛才我已經去交足了醫藥費,權當做善事,您不用管這些,安心養病就好。”

Our discovery and development platforms for drug and cell-based therapies allow us to both create and retain significant value within our therapeutic franchise areas of cancer and inflammatory diseases. Scientists and physicians at Celgene are the driving force behind our success, enabling target-to-therapeutic platforms that integrate both small-molecule and cell-based therapies.

Connect? Registries

The Connect??Registries are observational, hematologic patient registry studies in Multiple Myeloma (Connect?MM), Chronic Lymphocytic Leukemia (Connect?CLL) and Myelodysplastic Syndromes/Acute Myeloid Leukemia (Connect?MDS/AML) and are sponsored by Celgene Corporation. These studies are designed to observe the routine care of patients through the course of their disease. Unlike clinical trials, registries do not require or provide any specific medications or healthcare services, but leave those decisions to the treating doctors and their patients.
Connect? Registries logo